Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy

NCT04336722 is registered in ClinicalTrials.gov with Albireo, an Ipsen Company as lead sponsor.

NCT NCT04336722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04336722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy
Lead sponsor
Albireo, an Ipsen Company
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2020
Completion date
June 22, 2026
Enrollment
254 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

biliary atresia